Detalhe da pesquisa
1.
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Lancet Oncol
; 18(10): 1317-1326, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844816
2.
Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.
Front Immunol
; 14: 1130214, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36825018
3.
Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy.
Cancer Med
; 12(22): 20783-20797, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962239
4.
Refining endpoints in brain tumor clinical trials.
J Neurooncol
; 108(2): 227-30, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22451194
5.
Role of Fcγ receptors in HER2-targeted breast cancer therapy.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34992090
6.
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders.
Front Immunol
; 13: 1069444, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36685591
7.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 7(4): 573-584, 2021 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33480963
8.
Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
Am Heart J
; 157(5): 827-36, 836.e1, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19376308
9.
Adverse Drug Reaction vs Care Complication: Response to "Use of Colony-Stimulating Factors in Patients With Systemic Lupus Erythematous".
J Pharm Pract
; 37(2): 259-260, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36592453
10.
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Clin Cancer Res
; 13(5): 1367-73, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17332278
11.
Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
J Natl Cancer Inst Monogr
; (37): 27-30, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17951228
12.
Patient-reported outcomes to support medical product labeling claims: FDA perspective.
Value Health
; 10 Suppl 2: S125-37, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17995471
13.
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.
Cancer Chemother Pharmacol
; 74(1): 125-30, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24819685
14.
GCP data quality for early clinical development.
Clin Cancer Res
; 16(6): 1756-63, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20215550
15.
Patient-reported outcomes supporting anticancer product approvals.
J Clin Oncol
; 25(32): 5094-9, 2007 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-17991927
16.
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Oncologist
; 12(1): 107-13, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17227905
17.
Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.
J Clin Oncol
; 25(32): 5133-40, 2007 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-17991933